Table 2.
Characteristics a of NSCLC patients in relation to the presence of EGFR mutations.
| [ALL] | EGFR: Wild-Type |
EGFR: Mutated |
p-Value | N b | |
|---|---|---|---|---|---|
| N = 68 | N = 61 | N = 7 | |||
| Age | 68.5 [63.0; 73.2] | 68.0 [63.0; 73.0] | 71.0 [60.0; 73.5] | 0.76 | 68 |
| Gender: | 0.18 | 68 | |||
| F | 15 (22.1%) | 12 (19.7%) | 3 (42.9%) | ||
| M | 53 (77.9%) | 49 (80.3%) | 4 (57.1%) | ||
| Histological type | 0.05 | 68 | |||
| adenocarcinoma | 32 (47.1%) | 26 (42.6%) | 6 (85.7%) | ||
| squamous cell carcinoma | 36 (52.9%) | 35 (57.4%) | 1 (14.3%) | ||
| Stage: | 1 | 53 | |||
| 2 | 1 (1.89%) | 1 (2.00%) | 0 (0.00%) | ||
| 3 | 28 (52.8%) | 26 (52.0%) | 2 (66.7%) | ||
| 4 | 24 (45.3%) | 23 (46.0%) | 1 (33.3%) | ||
| Lymphocytes, ×103/µL | 1.51 [1.14; 2.02] | 1.49 [1.12; 2.06] | 1.99 [1.41; 2.00] | 0.54 | 61 |
| Neutrophils, ×103/µL | 7.72 [5.90; 10.4] | 7.70 [5.89; 9.97] | 7.92 [6.45; 10.5] | 0.79 | 61 |
| Platelets, ×103/µL | 330 [269; 426] | 334 [273; 428] | 281 [263; 337] | 0.58 | 61 |
| C-reactive protein, mg/L | 51.0 [17.2; 140] | 61.2 [20.8; 140] | 25.4 [10.2; 123] | 0.65 | 48 |
| Hemoglobin, g/dL | 12.8 [11.2; 13.9] | 13.0 [11.3; 14.0] | 11.8 [10.8; 12.3] | 0.38 | 58 |
| Smoking, packs/year | 35.0 [24.0; 50.0] | 40.0 [30.0; 50.0] | 5.00 [0.00; 17.5] | 0 | 65 |
| COPD: | 0 | 67 | |||
| no | 21 (31.3%) | 15 (24.6%) | 6 (100%) | ||
| yes | 46 (68.7%) | 46 (75.4%) | 0 (0.00%) | ||
| BMI, kg/m2 | 24.5 [19.9; 27.3] | 24.5 [20.3; 26.8] | 21.7 [17.9; 25.5] | 0.86 | 35 |
| NLR | 5.00 [3.20; 8.00] | 5.15 [3.25; 8.03] | 3.30 [3.20; 5.30] | 0.66 | 61 |
| PLR | 217 [150; 333] | 218 [151; 334] | 187 [141; 321] | 0.64 | 61 |
a Values are presented as numbers (percentages) for categorical variables and medians [interquartile range] for numerical variables. b Number of observations for a given variable. COPD = chronic obstructive pulmonary disease.